Bleakley Financial Group LLC Boosts Stock Position in Danaher Corporation $DHR

Bleakley Financial Group LLC grew its stake in shares of Danaher Corporation (NYSE:DHR) by 34.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 35,709 shares of the conglomerate’s stock after acquiring an additional 9,208 shares during the period. Bleakley Financial Group LLC’s holdings in Danaher were worth $8,175,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Elevated Capital Advisors LLC bought a new stake in Danaher during the fourth quarter worth about $26,000. JPL Wealth Management LLC purchased a new position in shares of Danaher in the 3rd quarter worth about $25,000. WFA of San Diego LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $26,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher during the 3rd quarter valued at about $27,000. Finally, Capco Asset Management LLC purchased a new position in shares of Danaher during the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Danaher stock opened at $172.12 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The stock’s 50 day simple moving average is $183.23 and its two-hundred day simple moving average is $208.40. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market cap of $121.82 billion, a price-to-earnings ratio of 33.29, a PEG ratio of 2.30 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm posted $1.88 EPS. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, analysts expect that Danaher Corporation will post 8.43 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s payout ratio is currently 30.95%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research reports. JPMorgan Chase & Co. decreased their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Rothschild & Co Redburn set a $205.00 price objective on Danaher in a report on Friday, April 17th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Evercore raised their price objective on Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a report on Tuesday, April 21st. Finally, Barclays decreased their price objective on Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Nineteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $238.65.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.